Compare GUG & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GUG | LXRX |
|---|---|---|
| Founded | N/A | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.0M | 547.4M |
| IPO Year | 2021 | 2000 |
| Metric | GUG | LXRX |
|---|---|---|
| Price | $15.83 | $1.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.97 |
| AVG Volume (30 Days) | 80.0K | ★ 2.3M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,081,000.00 |
| Revenue This Year | N/A | $56.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2481.48 |
| 52 Week Low | $13.90 | $0.32 |
| 52 Week High | $16.50 | $1.83 |
| Indicator | GUG | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 63.93 |
| Support Level | $15.46 | $1.08 |
| Resistance Level | $16.17 | $1.65 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 13.64 | 72.63 |
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.